Skip to main content

Cepheid s Q1 Revenues Grow 3 Percent As Net Loss Widens

NEW YORK, May 5 (GenomeWeb News) – Cepheid announced yesterday that its Q1 revenues increased 3 percent to $20.2 million from $19.6 million during the year-ago period, while its net loss grew 9.3 percent to $6.7 million from $3.5 million during the first quarter of 2005. Research and development costs grew 2.9 percent to $5.8 million from $4.5 million during the first quarter of 2005. As of March 31, Cepheid had $59.7 million in cash and cash equivalents.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.